These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15637605)

  • 1. Good faith gone bad-gone good again.
    Bialy H
    Nat Biotechnol; 2005 Jan; 23(1):17. PubMed ID: 15637605
    [No Abstract]   [Full Text] [Related]  

  • 2. Good faith gone bad.
    Bialy H
    Nat Biotechnol; 2000 Nov; 18(11):1123. PubMed ID: 11062389
    [No Abstract]   [Full Text] [Related]  

  • 3. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 4. On the road to California.
    DeWitt N
    Nature; 2002 Dec; 420(6916 Suppl):A9. PubMed ID: 12510695
    [No Abstract]   [Full Text] [Related]  

  • 5. BIO 2006 Annual International Convention. The current state of the global biotechnology industry.
    Zarkowska T
    IDrugs; 2006 Jun; 9(6):381-2. PubMed ID: 16752301
    [No Abstract]   [Full Text] [Related]  

  • 6. Industrial health research in Canada.
    Morin Y
    CMAJ; 2007 Jun; 176(12):1734; author reply 1734. PubMed ID: 17548390
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotechnology. French drug industry initiative.
    Anderson C
    Nature; 1991 Oct; 353(6344):487. PubMed ID: 1922346
    [No Abstract]   [Full Text] [Related]  

  • 8. Premier funds biotechnology.
    Scott L
    Mod Healthc; 1996 Apr; 26(18):50. PubMed ID: 10157168
    [No Abstract]   [Full Text] [Related]  

  • 9. Natural resources: bioprospects less than golden.
    Dalton R
    Nature; 2004 Jun; 429(6992):598-600. PubMed ID: 15190324
    [No Abstract]   [Full Text] [Related]  

  • 10. OECD says industrial biotech not realizing potential.
    Niiler E
    Nat Biotechnol; 2001 Jun; 19(6):493-4. PubMed ID: 11385413
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechnology consortia versus multifirm alliances: paradigm shift at work?
    Persidis A; Persidis A
    Nat Biotechnol; 1996 Dec; 14(13):1657-60. PubMed ID: 9634847
    [No Abstract]   [Full Text] [Related]  

  • 12. US drug industry's research support.
    Clemmitt M
    Nature; 1993 Feb; 361(6414):757-60. PubMed ID: 8441474
    [No Abstract]   [Full Text] [Related]  

  • 13. Celera buys Axys.
    Morrison C
    Nat Biotechnol; 2001 Aug; 19(8):703-5. PubMed ID: 11479548
    [No Abstract]   [Full Text] [Related]  

  • 14. R&D deals boom in 2004.
    Lawrence S
    Nat Biotechnol; 2005 Sep; 23(9):1036. PubMed ID: 16151383
    [No Abstract]   [Full Text] [Related]  

  • 15. BIO 2006 Annual International Convention. The expanding biotech industry of France.
    Zarkowska T
    IDrugs; 2006 Jun; 9(6):383-5. PubMed ID: 16752302
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotechnology in the Medicon Valley.
    Frank L
    Nature; 2002 Dec; 420(6916 Suppl):A27, A29, A31 passim. PubMed ID: 12501124
    [No Abstract]   [Full Text] [Related]  

  • 17. IPO floodgates unlikely to open after Ark floatation.
    Louët S
    Nat Biotechnol; 2004 Apr; 22(4):367-8. PubMed ID: 15060538
    [No Abstract]   [Full Text] [Related]  

  • 18. Patent threat in emerging economies shifts to biotech.
    Jayaranam K
    Nat Biotechnol; 2008 May; 26(5):481-3. PubMed ID: 18464760
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative effectiveness casts first shadows across US industry.
    Waltz E
    Nat Biotechnol; 2009 Mar; 27(3):211-2. PubMed ID: 19270651
    [No Abstract]   [Full Text] [Related]  

  • 20. Gold in the ivory tower: equity rewards of outlicensing.
    Edwards M; Murray F; Yu R
    Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.